As survival rates for blood cancers climb, the medical community faces a growing challenge: managing the cumulative burden of radiation side effects across increasingly long survivorship periods. This review addresses a gap that conventional oncology has historically underserved — the systematic use of integrative medicine to reduce toxicities and improve quality of life for lymphoma, leukemia, and plasmacytoma patients.
The review, published in Seminars in Radiation Oncology, synthesizes current evidence across several integrative modalities applied to radiation-related toxicities. Mindfulness-based interventions and yoga emerged with the strongest evidentiary support, particularly for managing radiation-induced fatigue, anxiety, and depression — symptoms that significantly impair treatment adherence and recovery. Acupuncture demonstrated efficacy across three distinct toxicity domains: pain management, xerostomia (radiation-related dry mouth), and anxiety reduction. The review also addresses the intersection of novel hematological therapies — including CAR-T cell therapy and bispecific antibodies — with radiation, noting that these combinations produce unique and compounding side effect profiles that integrative protocols may need to specifically address.
This synthesis arrives at a clinically meaningful moment. Survivorship care in hematological malignancies now extends decades, meaning radiation-associated risks — cardiovascular damage, secondary malignancy development, and psychosocial sequelae — accumulate over time. Integrative approaches offer a potentially low-risk, patient-centered layer of care that conventional oncology protocols rarely formalize. However, significant limitations remain: much of the underlying trial data involves small cohorts, heterogeneous patient populations, and inconsistent intervention protocols, making standardization difficult. The evidence base for acupuncture, while encouraging, remains lower in methodological rigor than for mindfulness-based interventions. This review is best understood as a useful consolidation of emerging clinical signals rather than a practice-changing mandate — valuable for informing multidisciplinary survivorship programs, but awaiting larger randomized trials before definitive guidelines can be established.